Meeting
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-sensitive prostate cancer.
Authors
Maral DerSarkissian
Analysis Group, Inc., Los Angeles, CA
Maral DerSarkissian , Deepshekhar Gupta , Jasmina Ivanova , Alexander Niyazov , Enrico Zanardo , Tracy Guo , Jingru Wang , Mei Sheng Duh , Stephen J. Freedland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Cancer Disparities
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 26)
DOI
10.1200/JCO.2023.41.6_suppl.26
Abstract #
26
Poster Bd #
A10
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.
First Author: Joelle Helou
Poster
2024 ASCO Genitourinary Cancers Symposium
A real-world observational study characterizing patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with or without androgen receptor pathway inhibitors (ARPIs).
First Author: Michael Paul Kolinsky
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan